TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Activation differences in neural regions serving motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postprandial blood plasma concentration of GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glycemic profile (fasting glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RBC Transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Length of hospital and intensive care unit stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Patients Who Experienced an Ultrasonographically-confirmed Venous Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage of subjects reached the IgG level of ≥0.35 µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMCs level for IgG antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wear of bulk filled resin-based composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change of Brain Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Axillary Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Rectal Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Bladder Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat attenuation index (FAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak and Nadir Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differences in platelet function assessed by aggregometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Electrophysiological intraoperative event score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of new sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work Limitations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Dopamine transporter density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dose-Normalized Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid levels (TC, TG, LDL-C, HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Daily Peripheral Neuropathic Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Comfort at End of Day
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distance walked during the 6 Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete healing of target ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Back Pain Intensity Scale (0 to 100 mm VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roland Disability Questionnaire (RDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: hand-to-floor distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CMV shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: X-ray induced genetic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of patients achieving hemodynamic stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function as determined by brachial artery Flow-Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fMRI-detected glymphatic flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG slow wave activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance (psychomotor vigilance test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction of chronic post-surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of protocol-specified assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful use of activity monitor
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Arterial Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bothersomeness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Type and duration of immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hours of Sitting Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disruptive Behavior Disorders Rating (DBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile characterized by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics characterized by plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change scores on Fugl Meyer- Upper Extremity Section
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Complete Response (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSAS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of HIV-1 in lymph node derived cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnosis accuracy (false negatives and false positives)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident of AKI-D patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Body fat percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in serum PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retention rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: session duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Assessment of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flash visual-evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urines positive for benzoylecgonine (BE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Quality of Life EORTC QLQ C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With HbA1c Level of Less Than 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean HbA1c Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ten meter walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extubation Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relative bioavailability of valsartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax - Peak Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-12h) - AUC From Time Zero to 12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid stimulating hormone (TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Free triiodothyronine (fT3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Free thyroxine (fT4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Occurrence and relationship to vaccination of any serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence, intensity and relationship to vaccination of clinically significant abnormal haematology and biochemistry values (grade 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in fibrous cap thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of health related quality of life (HRQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Need of renal replacement treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-h blood glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sum of pain intensity differences (PIDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of total of pain relief and pain intensity differences (SPRID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Immunologic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Viral Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HPV vaccination uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pathologic complete response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of coronary artery dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to healing of ischemic digital ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: prevalence of malaria positive individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average VAS pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum concentrations of 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum concentrations of PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Advanced Oxidation Protein Products (AOPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Body Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Worst Case Abnormal Electrocardiogram (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Internalizing Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Externalizing Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adaptive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients presenting with related DLT
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of patients with complete haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Marginal Bone Level Alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor genotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acute renal function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inflammatory profile changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Snellen BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epiretinal membrane formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Reaction and Occupational Illness
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase II Dose (RPTD) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal protection measures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Capillary blood glucose measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of SAP within 7 days after stroke onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Who Remained Stable for 52 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications of ICD
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to HIV medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methamphetamine use
Endpoint domain: Adverse events/effects
Primary endpoint: Cup Migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Femoral stem migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titers ≥40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major adverse cardiac and cerebrovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with abnormal laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with adverse events related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Substance Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in Quality of Life: Perceived General Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in Quality of Life: Unhealthy Days or Days Limited by Poor Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ventilator-free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in opioid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of Microvascular Resistance (IMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hours of Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinically significant abnormality in visual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scalp surface area affected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CO2 removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in probing pocket depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bleeding on probing (BOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in clinical attachment loss (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plaque index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Conformity of nursing care in enteral nutritional therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse drug reactions of bone marrow depression
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Satisfaction with Therapy and Therapist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Credibility/Expectancy Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional Assessment of Currently Employed Technology Scale (FACETS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent of Group Therapy Sessions Attended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Radial artery access site intimal-medial thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Study Drug Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Completion of at Least 2 Study Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Rated the Intervention Acceptable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of binge eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Testosterone to cortisol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clearance of malaria parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: neurophysiological measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change in Composite Observer Score for POSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change in Composite Patient Score for POSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absolute change in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in total score of Overactive Bladder Symptom Scale (OABSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EULAR Sjögren Syndrome Patient Reported Index (ESSPRI) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Histological response to neoadjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ventilation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Liver dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in functional disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disappearance of clinical symptoms linked to C. difficile infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: prognostic value of Thyroseq v2 molecular/genomic profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concordance of responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of nurse assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tolerability of the bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a Recurrent Seizure After Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Lateral Wall Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: urinary culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Renal function (evaluated by level of Serum Creatinine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of New-Onset Diabetes Mellitus After Transplant (NODAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Event rate of patients with biopsy-confirmed acute rejections (BCAR) ≥ Grade I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: No sustained ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Died From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Were Hospitalized
Endpoint domain: Resource use
Endpoint subdomain: Hospital